If they have worked out the timing right then no CR will be...

If they have worked out the timing right then no CR will be needed, there's 18m options with a strike price of 20 cents expiring end of year, if all those are converted then this will bring in $3.6m of much needed working capital, realistically the share price will need to hold around 30 cents for this to occur, with the testing today proving that Path-away is 99.9% effective against the actual human strain and being an all organic natural product approvals for this should come in thick and fast.

When approvals (List N and TGA) are granted, order's should flow in from government departments across multiple countries, the NHS would be my guess as to one of the many larger sized ones currently eyeing this product up, on top of that you have airports, shopping malls and many other privately owned facilities, it really is going to be a snowball effect here given its one of a kind nature, Don't put too much emphasis over how this trades over the coming few days, this is now a very serious money making long term hold.

Also worth mentioning is the nasal balm which we haven't heard any real news on since its delayed July launch, that product alone could bring in 10's of millions in revenue - especially now its been officially proven against the human strain, this needs to launch ASAP imo as there is currently a product in development by another company, first in the door with this kind of product will cut off any competitors chances drastically so they should really be focusing on pushing that to market as soon as they can.